Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hippocampus | 10 | 2010 | 546 | 0.880 |
Why?
|
| Long-Term Potentiation | 5 | 2010 | 99 | 0.860 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 2 | 2014 | 8 | 0.780 |
Why?
|
| Receptors, Dopamine D1 | 2 | 2015 | 35 | 0.780 |
Why?
|
| Benzazepines | 5 | 2015 | 29 | 0.770 |
Why?
|
| Glucose Intolerance | 1 | 2018 | 42 | 0.670 |
Why?
|
| Sleep Deprivation | 1 | 2018 | 23 | 0.660 |
Why?
|
| GAP-43 Protein | 2 | 2006 | 9 | 0.550 |
Why?
|
| Catha | 1 | 2015 | 1 | 0.550 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2015 | 10 | 0.550 |
Why?
|
| Methamphetamine | 3 | 2014 | 155 | 0.550 |
Why?
|
| Alkaloids | 1 | 2015 | 38 | 0.530 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2015 | 68 | 0.520 |
Why?
|
| Dopamine Agents | 1 | 2014 | 24 | 0.490 |
Why?
|
| Guinea Pigs | 8 | 2015 | 141 | 0.470 |
Why?
|
| Locomotion | 1 | 2014 | 91 | 0.460 |
Why?
|
| Plant Extracts | 1 | 2015 | 250 | 0.440 |
Why?
|
| Synaptic Transmission | 3 | 2010 | 141 | 0.360 |
Why?
|
| Benzoxazines | 2 | 2019 | 46 | 0.320 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 29 | 0.280 |
Why?
|
| Animals | 17 | 2015 | 14307 | 0.240 |
Why?
|
| Synapses | 4 | 1992 | 173 | 0.230 |
Why?
|
| Electric Stimulation | 7 | 2006 | 177 | 0.230 |
Why?
|
| Electrophysiology | 3 | 2001 | 130 | 0.230 |
Why?
|
| Gene Expression | 1 | 2006 | 639 | 0.230 |
Why?
|
| Neurophysiology | 1 | 2001 | 8 | 0.210 |
Why?
|
| Functional Laterality | 1 | 2001 | 75 | 0.200 |
Why?
|
| Presynaptic Terminals | 1 | 2001 | 52 | 0.200 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 184 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 984 | 0.180 |
Why?
|
| HIV Infections | 3 | 2019 | 2207 | 0.180 |
Why?
|
| Neurons | 5 | 2011 | 1130 | 0.180 |
Why?
|
| Male | 12 | 2018 | 18870 | 0.170 |
Why?
|
| Models, Biological | 1 | 2001 | 642 | 0.160 |
Why?
|
| Pregnant Women | 1 | 2018 | 48 | 0.160 |
Why?
|
| Jaundice | 1 | 2018 | 7 | 0.160 |
Why?
|
| HIV Protease Inhibitors | 1 | 2018 | 22 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2018 | 25 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 336 | 0.160 |
Why?
|
| Steroid Hydroxylases | 1 | 2016 | 3 | 0.150 |
Why?
|
| Central Nervous System Diseases | 1 | 2016 | 27 | 0.140 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2016 | 55 | 0.140 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2016 | 49 | 0.140 |
Why?
|
| Electrolytes | 1 | 2016 | 25 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 638 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2018 | 628 | 0.140 |
Why?
|
| Minerals | 1 | 2016 | 45 | 0.140 |
Why?
|
| Sulpiride | 1 | 2015 | 6 | 0.140 |
Why?
|
| Masseter Muscle | 2 | 1992 | 4 | 0.140 |
Why?
|
| Incidence | 1 | 2018 | 882 | 0.140 |
Why?
|
| Malnutrition | 1 | 2016 | 45 | 0.140 |
Why?
|
| Vitamins | 1 | 2016 | 91 | 0.130 |
Why?
|
| Motor Activity | 2 | 2015 | 393 | 0.130 |
Why?
|
| Lipids | 1 | 2016 | 222 | 0.130 |
Why?
|
| Dietary Supplements | 1 | 2016 | 196 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2006 | 528 | 0.120 |
Why?
|
| HIV-1 | 1 | 2019 | 678 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2015 | 165 | 0.120 |
Why?
|
| Pregnancy | 1 | 2018 | 1503 | 0.120 |
Why?
|
| Aging | 2 | 2022 | 639 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2006 | 834 | 0.110 |
Why?
|
| Female | 6 | 2018 | 19873 | 0.110 |
Why?
|
| Mandibular Nerve | 1 | 1992 | 2 | 0.110 |
Why?
|
| Neural Conduction | 1 | 1992 | 19 | 0.110 |
Why?
|
| Action Potentials | 6 | 2001 | 219 | 0.110 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2011 | 45 | 0.100 |
Why?
|
| Chlorides | 1 | 2011 | 52 | 0.100 |
Why?
|
| Strychnine | 1 | 1991 | 2 | 0.100 |
Why?
|
| Reticular Formation | 1 | 1991 | 4 | 0.100 |
Why?
|
| Bicuculline | 1 | 1991 | 14 | 0.100 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 212 | 0.100 |
Why?
|
| alpha-Synuclein | 1 | 2011 | 48 | 0.100 |
Why?
|
| Young Adult | 2 | 2018 | 4012 | 0.100 |
Why?
|
| Motor Neurons | 1 | 1991 | 72 | 0.100 |
Why?
|
| Adult | 4 | 2018 | 11034 | 0.100 |
Why?
|
| Dopamine Antagonists | 2 | 2010 | 39 | 0.090 |
Why?
|
| Risk Factors | 1 | 2018 | 3414 | 0.090 |
Why?
|
| Sleep | 1 | 1991 | 122 | 0.090 |
Why?
|
| Humans | 10 | 2022 | 34853 | 0.090 |
Why?
|
| Bupivacaine | 1 | 1989 | 1 | 0.090 |
Why?
|
| Menisci, Tibial | 1 | 1989 | 3 | 0.090 |
Why?
|
| Pain, Postoperative | 1 | 1989 | 22 | 0.090 |
Why?
|
| Substance-Related Disorders | 2 | 2008 | 685 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2008 | 33 | 0.080 |
Why?
|
| Cyclopropanes | 2 | 2019 | 39 | 0.080 |
Why?
|
| Alkynes | 2 | 2019 | 49 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2015 | 1802 | 0.070 |
Why?
|
| Enflurane | 1 | 1986 | 1 | 0.070 |
Why?
|
| Rats | 5 | 2008 | 3261 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2006 | 137 | 0.070 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2005 | 17 | 0.070 |
Why?
|
| Autoradiography | 1 | 2005 | 36 | 0.070 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 125 | 0.060 |
Why?
|
| Genotype | 2 | 2018 | 641 | 0.060 |
Why?
|
| Time Factors | 2 | 2005 | 1681 | 0.060 |
Why?
|
| Ibogaine | 1 | 2002 | 2 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 859 | 0.050 |
Why?
|
| Depression | 1 | 2008 | 664 | 0.050 |
Why?
|
| Cats | 2 | 1992 | 65 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 58 | 0.050 |
Why?
|
| Homeostasis | 1 | 2022 | 172 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 137 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 45 | 0.040 |
Why?
|
| Picrotoxin | 2 | 1988 | 10 | 0.040 |
Why?
|
| Middle Aged | 3 | 2018 | 9642 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 187 | 0.040 |
Why?
|
| Bilirubin | 1 | 2018 | 17 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 102 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2002 | 968 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2016 | 29 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2016 | 17 | 0.040 |
Why?
|
| Zambia | 1 | 2016 | 37 | 0.040 |
Why?
|
| Phosphates | 1 | 2016 | 49 | 0.040 |
Why?
|
| Magnesium | 1 | 2016 | 95 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2016 | 115 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 424 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 394 | 0.030 |
Why?
|
| Mice | 3 | 2011 | 5668 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2016 | 114 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 139 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 214 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 528 | 0.030 |
Why?
|
| Brain | 2 | 2011 | 1268 | 0.030 |
Why?
|
| Myelin Sheath | 1 | 1992 | 42 | 0.030 |
Why?
|
| Muscle Development | 1 | 1992 | 44 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1992 | 186 | 0.030 |
Why?
|
| Saccharin | 1 | 1992 | 6 | 0.030 |
Why?
|
| Axons | 1 | 1992 | 106 | 0.030 |
Why?
|
| Cricetulus | 1 | 2011 | 74 | 0.030 |
Why?
|
| CHO Cells | 1 | 2011 | 107 | 0.030 |
Why?
|
| Cricetinae | 1 | 2011 | 217 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2011 | 214 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 1991 | 47 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 173 | 0.020 |
Why?
|
| Cerebral Cortex | 2 | 1992 | 274 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2010 | 22 | 0.020 |
Why?
|
| Aged | 1 | 2022 | 6448 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2011 | 119 | 0.020 |
Why?
|
| Dopamine | 1 | 2011 | 232 | 0.020 |
Why?
|
| Piperazines | 1 | 2010 | 109 | 0.020 |
Why?
|
| Injections, Intra-Articular | 1 | 1989 | 1 | 0.020 |
Why?
|
| Arthroscopy | 1 | 1989 | 2 | 0.020 |
Why?
|
| Analgesia | 1 | 1989 | 20 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 1986 | 132 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2008 | 38 | 0.020 |
Why?
|
| Motor Endplate | 1 | 1988 | 3 | 0.020 |
Why?
|
| Barium | 1 | 1988 | 15 | 0.020 |
Why?
|
| Tetany | 1 | 1988 | 2 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 117 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 139 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 1988 | 33 | 0.020 |
Why?
|
| Neuromuscular Junction | 1 | 1988 | 33 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1989 | 269 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 165 | 0.020 |
Why?
|
| Neuroglia | 1 | 1988 | 117 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1989 | 195 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1988 | 480 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2008 | 304 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2008 | 897 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 1530 | 0.020 |
Why?
|
| Peptides | 1 | 1988 | 308 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 5035 | 0.020 |
Why?
|
| Verapamil | 1 | 1984 | 6 | 0.020 |
Why?
|
| Kinetics | 1 | 1986 | 650 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1534 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2008 | 541 | 0.010 |
Why?
|
| Tabernaemontana | 1 | 2002 | 2 | 0.010 |
Why?
|
| Hallucinogens | 1 | 2002 | 25 | 0.010 |
Why?
|
| Evoked Potentials | 2 | 1992 | 83 | 0.010 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1992 | 5 | 0.010 |
Why?
|
| Quinoxalines | 1 | 1992 | 27 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 1992 | 41 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1992 | 84 | 0.010 |
Why?
|
| Neurites | 1 | 1992 | 35 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1992 | 213 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1992 | 131 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 1988 | 11 | 0.010 |
Why?
|
| Rabbits | 1 | 1988 | 278 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1988 | 1442 | 0.000 |
Why?
|
| Dendrites | 1 | 1984 | 52 | 0.000 |
Why?
|
| Calcium | 1 | 1984 | 445 | 0.000 |
Why?
|